Knight Therapeutics Competitors

Knight Therapeutics (TSE:GUD) and Leaf Mobile (TSE:LEAF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Valuation & Earnings

This table compares Knight Therapeutics and Leaf Mobile's top-line revenue, earnings per share (EPS) and valuation.

Knight Therapeutics has higher revenue and earnings than Leaf Mobile. Leaf Mobile is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Knight Therapeutics and Leaf Mobile's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Knight Therapeutics and Leaf Mobile, as provided by MarketBeat.

Knight Therapeutics presently has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Leaf Mobile has a consensus price target of C$0.88, suggesting a potential upside of 103.49%. Given Leaf Mobile's higher possible upside, analysts plainly believe Leaf Mobile is more favorable than Knight Therapeutics.

Summary

Knight Therapeutics beats Leaf Mobile on 5 of the 7 factors compared between the two stocks.

Aurora Cannabis (TSE:ACB) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Aurora Cannabis and Knight Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Aurora Cannabis and Knight Therapeutics' revenue, earnings per share (EPS) and valuation.

Knight Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Aurora Cannabis and Knight Therapeutics, as provided by MarketBeat.

Aurora Cannabis presently has a consensus price target of C$9.79, suggesting a potential upside of 18.13%. Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Aurora Cannabis.

Summary

Knight Therapeutics beats Aurora Cannabis on 6 of the 8 factors compared between the two stocks.

HEXO (TSE:HEXO) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

Valuation and Earnings

This table compares HEXO and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Knight Therapeutics has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for HEXO and Knight Therapeutics, as reported by MarketBeat.

HEXO presently has a consensus price target of C$1.79, indicating a potential downside of 75.79%. Knight Therapeutics has a consensus price target of C$7.88, indicating a potential upside of 47.20%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than HEXO.

Profitability

This table compares HEXO and Knight Therapeutics' net margins, return on equity and return on assets.

Summary

Knight Therapeutics beats HEXO on 7 of the 9 factors compared between the two stocks.

Knight Therapeutics (TSE:GUD) and OrganiGram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Knight Therapeutics and OrganiGram's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and price targets for Knight Therapeutics and OrganiGram, as reported by MarketBeat.

Knight Therapeutics presently has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. OrganiGram has a consensus price target of C$3.78, suggesting a potential upside of 28.47%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Knight Therapeutics is more favorable than OrganiGram.

Earnings & Valuation

This table compares Knight Therapeutics and OrganiGram's gross revenue, earnings per share (EPS) and valuation.

Knight Therapeutics has higher revenue and earnings than OrganiGram. OrganiGram is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Knight Therapeutics beats OrganiGram on 7 of the 8 factors compared between the two stocks.

HLS Therapeutics (TSE:HLS) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Valuation and Earnings

This table compares HLS Therapeutics and Knight Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Knight Therapeutics has higher revenue and earnings than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for HLS Therapeutics and Knight Therapeutics, as provided by MarketBeat.com.

HLS Therapeutics presently has a consensus price target of C$30.50, suggesting a potential upside of 77.02%. Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given HLS Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe HLS Therapeutics is more favorable than Knight Therapeutics.

Profitability

This table compares HLS Therapeutics and Knight Therapeutics' net margins, return on equity and return on assets.

Summary

Knight Therapeutics beats HLS Therapeutics on 5 of the 9 factors compared between the two stocks.

ICC Labs (CVE:ICC) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, analyst recommendations and valuation.

Valuation and Earnings

This table compares ICC Labs and Knight Therapeutics' gross revenue, earnings per share and valuation.

Knight Therapeutics has higher revenue and earnings than ICC Labs. Knight Therapeutics is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for ICC Labs and Knight Therapeutics, as reported by MarketBeat.

Knight Therapeutics has a consensus price target of C$7.88, suggesting a potential upside of 47.20%. Given Knight Therapeutics' higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than ICC Labs.

Profitability

This table compares ICC Labs and Knight Therapeutics' net margins, return on equity and return on assets.

Summary

Knight Therapeutics beats ICC Labs on 5 of the 7 factors compared between the two stocks.